Aug. 16 at 9:54 PM
$INSM Mizuho new modeling base case PT of
$192 is based on key assumptions around (1) current ongoing launches of currently approved Arikayce in refractory NTM-MAC &brensocatib in NCFBE, as well as launch timings of Arikayce in front-line NTM-MAC, and TPIP in PH-ILD, PAH, and IPF (2) speed of market adoptions and depth of market penetration in all of INSM’s indications, and (3) LOE assumptions and potential generic entry, where notably, do not assume any LOE for INSM’s products.
bull case is
$280; this primarily assumes 80% peak market share for brensocatib in NCFBE (vs. current base case 65% peak market share”
